Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 252

1.

Use of a plastic scintillator detector for patient-specific quality assurance of VMAT SRS.

Snyder JD, Sullivan RJ, Wu X, Covington EL, Popple RA.

J Appl Clin Med Phys. 2019 Sep;20(9):143-148. doi: 10.1002/acm2.12705.

PMID:
31538717
2.

Are There Gender Differences Among Leaders of Regional Orthopaedic Societies of the United States?

Gwam CU, Rosas S, Xiao T, Dawkins A, Sullivan RJ, Emory CL.

Clin Orthop Relat Res. 2019 Aug 30. doi: 10.1097/CORR.0000000000000956. [Epub ahead of print]

PMID:
31490352
3.

Anti-PD-1-induced pneumonitis is associated with persistent imaging abnormalities in melanoma patients.

Johnson DB, Taylor KB, Cohen JV, Ayoubi N, Haugh AM, Wang DY, Schlick BD, Voorhees AL, Gage KL, Fintelmann FJ, Sullivan RJ, Eroglu Z, Abramson RG.

Cancer Immunol Res. 2019 Aug 28. pii: canimm.0717.2018. doi: 10.1158/2326-6066.CIR-18-0717. [Epub ahead of print]

PMID:
31462410
4.

Varied phenotypes and management of immune checkpoint inhibitor-associated neuropathies.

Dubey D, David WS, Amato AA, Reynolds KL, Clement NF, Chute DF, Cohen JV, Lawrence DP, Mooradian MJ, Sullivan RJ, Guidon AC.

Neurology. 2019 Sep 10;93(11):e1093-e1103. doi: 10.1212/WNL.0000000000008091. Epub 2019 Aug 12.

PMID:
31405908
5.

A fatty acid oxidation-dependent metabolic shift regulates the adaptation of BRAF-mutated melanoma to MAPK inhibitors.

Aloia A, Müllhaupt D, Chabbert CD, Eberhart T, Flueckiger S, Vukolic A, Eichhoff OM, Irmisch A, Alexander LT, Scibona E, Frederick DT, Miao B, Tian T, Cheng C, Kwong LN, Wei Z, Sullivan RJ, Boland GM, Herlyn M, Flaherty KT, Zamboni N, Dummer R, Zhang G, Levesque MP, Krek W, Kovacs WJ.

Clin Cancer Res. 2019 Aug 2. pii: clincanres.0253.2019. doi: 10.1158/1078-0432.CCR-19-0253. [Epub ahead of print]

PMID:
31375515
6.

PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance.

Verma V, Shrimali RK, Ahmad S, Dai W, Wang H, Lu S, Nandre R, Gaur P, Lopez J, Sade-Feldman M, Yizhak K, Bjorgaard SL, Flaherty KT, Wargo JA, Boland GM, Sullivan RJ, Getz G, Hammond SA, Tan M, Qi J, Wong P, Merghoub T, Wolchok J, Hacohen N, Janik JE, Mkrtichyan M, Gupta S, Khleif SN.

Nat Immunol. 2019 Sep;20(9):1231-1243. doi: 10.1038/s41590-019-0441-y. Epub 2019 Jul 29.

PMID:
31358999
7.

Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium.

Amaria RN, Menzies AM, Burton EM, Scolyer RA, Tetzlaff MT, Antdbacka R, Ariyan C, Bassett R, Carter B, Daud A, Faries M, Fecher LA, Flaherty KT, Gershenwald JE, Hamid O, Hong A, Kirkwood JM, Lo S, Margolin K, Messina J, Postow MA, Rizos H, Ross MI, Rozeman EA, Saw RPM, Sondak V, Sullivan RJ, Taube JM, Thompson JF, van de Wiel BA, Eggermont AM, Davies MA; International Neoadjuvant Melanoma Consortium members, Ascierto PA, Spillane AJ, van Akkooi ACJ, Wargo JA, Blank CU, Tawbi HA, Long GV.

Lancet Oncol. 2019 Jul;20(7):e378-e389. doi: 10.1016/S1470-2045(19)30332-8. Review.

PMID:
31267972
8.

Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients.

Sullivan RJ, Hamid O, Gonzalez R, Infante JR, Patel MR, Hodi FS, Lewis KD, Tawbi HA, Hernandez G, Wongchenko MJ, Chang Y, Roberts L, Ballinger M, Yan Y, Cha E, Hwu P.

Nat Med. 2019 Jun;25(6):929-935. doi: 10.1038/s41591-019-0474-7. Epub 2019 Jun 6.

PMID:
31171876
9.

Back to the Future: Rethinking and Retooling IL2 in the Immune Checkpoint Inhibitor Era.

Sullivan RJ.

Cancer Discov. 2019 Jun;9(6):694-695. doi: 10.1158/2159-8290.CD-19-0412.

PMID:
31160329
10.

Immunotherapeutic strategies for cutaneous squamous cell carcinoma prevention in xeroderma pigmentosum.

Ameri AH, Mooradian MJ, Emerick KS, Park JC, Wirth LJ, Asgari MM, Tsao H, Lawrence D, Sullivan RJ, Demehri S.

Br J Dermatol. 2019 May 18. doi: 10.1111/bjd.18144. [Epub ahead of print] No abstract available.

PMID:
31102460
11.

Frontline Therapy for BRAF-Mutated Metastatic Melanoma: How Do You Choose, and Is There One Correct Answer?

Pavlick AC, Fecher L, Ascierto PA, Sullivan RJ.

Am Soc Clin Oncol Educ Book. 2019 Jan;39:564-571. doi: 10.1200/EDBK_243071. Epub 2019 May 17.

PMID:
31099689
12.

The metastatic dissemination of a squamous cell carcinoma arising from an epidermal cyst and subsequent failure to respond to programmed death 1 inhibition.

Lumish MA, Anderson MA, Rush PS, Fintelmann FJ, Duncan L, Sullivan RJ, Mooradian MJ.

JAAD Case Rep. 2019 Apr 5;5(4):375-378. doi: 10.1016/j.jdcr.2019.01.032. eCollection 2019 Apr. No abstract available.

13.

Developments in the Space of New MAPK Pathway Inhibitors for BRAF-Mutant Melanoma.

Cohen JV, Sullivan RJ.

Clin Cancer Res. 2019 Apr 16. doi: 10.1158/1078-0432.CCR-18-0836. [Epub ahead of print] Review.

PMID:
30992297
14.

What to Do When Anti-PD-1 Therapy Fails in Patients With Melanoma.

Mooradian MJ, Sullivan RJ.

Oncology (Williston Park). 2019 Apr 15;33(4):141-8. Review.

15.

The future of combination treatment with checkpoint inhibitors in melanoma.

Sullivan RJ.

Clin Adv Hematol Oncol. 2019 Feb;17(2):96-99. No abstract available.

PMID:
30845111
16.

Solving the problem with stannous fluoride: Formulation, stabilization, and antimicrobial action.

Myers CP, Pappas I, Makwana E, Begum-Gafur R, Utgikar N, Alsina MA, Fitzgerald M, Trivedi HM, Gaillard JF, Masters JG, Sullivan RJ.

J Am Dent Assoc. 2019 Apr;150(4S):S5-S13. doi: 10.1016/j.adaj.2019.01.004.

PMID:
30797260
17.

Influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors.

Awadalla M, Golden DLA, Mahmood SS, Alvi RM, Mercaldo ND, Hassan MZO, Banerji D, Rokicki A, Mulligan C, Murphy SPT, Jones-O'Connor M, Cohen JV, Heinzerling LM, Armanious M, Sullivan RJ, Damrongwatanasuk R, Chen CL, Gupta D, Kirchberger MC, Moslehi JJ, Shah SP, Ganatra S, Thavendiranathan P, Rizvi MA, Sahni G, Lyon AR, Tocchetti CG, Mercurio V, Thuny F, Ederhy S, Mahmoudi M, Lawrence DP, Groarke JD, Nohria A, Fradley MG, Reynolds KL, Neilan TG.

J Immunother Cancer. 2019 Feb 22;7(1):53. doi: 10.1186/s40425-019-0535-y.

18.

Treatment of Peritrochanteric Femur Fractures With Proximal Femur Locked Plating.

Medda S, Sullivan RJ, Marquez-Lara A, Araiza ET, Pilson HT, Halvorson JJ, Carroll EA.

J Orthop Trauma. 2019 Jul;33(7):341-345. doi: 10.1097/BOT.0000000000001442.

PMID:
30730363
19.

Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma.

Sade-Feldman M, Yizhak K, Bjorgaard SL, Ray JP, de Boer CG, Jenkins RW, Lieb DJ, Chen JH, Frederick DT, Barzily-Rokni M, Freeman SS, Reuben A, Hoover PJ, Villani AC, Ivanova E, Portell A, Lizotte PH, Aref AR, Eliane JP, Hammond MR, Vitzthum H, Blackmon SM, Li B, Gopalakrishnan V, Reddy SM, Cooper ZA, Paweletz CP, Barbie DA, Stemmer-Rachamimov A, Flaherty KT, Wargo JA, Boland GM, Sullivan RJ, Getz G, Hacohen N.

Cell. 2019 Jan 10;176(1-2):404. doi: 10.1016/j.cell.2018.12.034. No abstract available.

20.

High Throughput Strategies for the Discovery and Optimization of Catalytic Reactions.

Isbrandt ES, Sullivan RJ, Newman SG.

Angew Chem Int Ed Engl. 2019 May 27;58(22):7180-7191. doi: 10.1002/anie.201812534. Epub 2019 Mar 12. Review.

PMID:
30576045
21.

Author Correction: PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas.

Lu H, Liu S, Zhang G, Wu B, Zhu Y, Frederick DT, Hu Y, Zhong W, Randell S, Sadek N, Zhang W, Chen G, Cheng C, Zeng J, Wu LW, Zhang J, Liu X, Xu W, Krepler C, Sproesser K, Xiao M, Miao B, Liu J, Song CD, Liu JY, Karakousis GC, Schuchter LM, Lu Y, Mills G, Cong Y, Chernoff J, Guo J, Boland GM, Sullivan RJ, Wei Z, Field J, Amaravadi RK, Flaherty KT, Herlyn M, Xu X, Guo W.

Nature. 2019 Jan;565(7738):E4. doi: 10.1038/s41586-018-0814-7.

PMID:
30532003
22.

Tolerance and efficacy of BRAF plus MEK inhibition in patients with melanoma who previously have received programmed cell death protein 1-based therapy.

Saab KR, Mooradian MJ, Wang DY, Chon J, Xia CY, Bialczak A, Abbate KT, Menzies AM, Johnson DB, Sullivan RJ, Shoushtari AN.

Cancer. 2019 Mar 15;125(6):884-891. doi: 10.1002/cncr.31889. Epub 2018 Dec 6.

PMID:
30521084
23.

Musculoskeletal rheumatic complications of immune checkpoint inhibitor therapy: A single center experience.

Mooradian MJ, Nasrallah M, Gainor JF, Reynolds KL, Cohen JV, Lawrence DP, Miloslavsky EM, Kohler MJ, Sullivan RJ, Schoenfeld SR.

Semin Arthritis Rheum. 2019 Jun;48(6):1127-1132. doi: 10.1016/j.semarthrit.2018.10.012. Epub 2018 Oct 16.

PMID:
30409415
24.

Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma.

Sade-Feldman M, Yizhak K, Bjorgaard SL, Ray JP, de Boer CG, Jenkins RW, Lieb DJ, Chen JH, Frederick DT, Barzily-Rokni M, Freeman SS, Reuben A, Hoover PJ, Villani AC, Ivanova E, Portell A, Lizotte PH, Aref AR, Eliane JP, Hammond MR, Vitzthum H, Blackmon SM, Li B, Gopalakrishnan V, Reddy SM, Cooper ZA, Paweletz CP, Barbie DA, Stemmer-Rachamimov A, Flaherty KT, Wargo JA, Boland GM, Sullivan RJ, Getz G, Hacohen N.

Cell. 2018 Nov 1;175(4):998-1013.e20. doi: 10.1016/j.cell.2018.10.038. Erratum in: Cell. 2019 Jan 10;176(1-2):404.

PMID:
30388456
25.

A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade.

Jerby-Arnon L, Shah P, Cuoco MS, Rodman C, Su MJ, Melms JC, Leeson R, Kanodia A, Mei S, Lin JR, Wang S, Rabasha B, Liu D, Zhang G, Margolais C, Ashenberg O, Ott PA, Buchbinder EI, Haq R, Hodi FS, Boland GM, Sullivan RJ, Frederick DT, Miao B, Moll T, Flaherty KT, Herlyn M, Jenkins RW, Thummalapalli R, Kowalczyk MS, Cañadas I, Schilling B, Cartwright ANR, Luoma AM, Malu S, Hwu P, Bernatchez C, Forget MA, Barbie DA, Shalek AK, Tirosh I, Sorger PK, Wucherpfennig K, Van Allen EM, Schadendorf D, Johnson BE, Rotem A, Rozenblatt-Rosen O, Garraway LA, Yoon CH, Izar B, Regev A.

Cell. 2018 Nov 1;175(4):984-997.e24. doi: 10.1016/j.cell.2018.09.006.

PMID:
30388455
26.

Clinical experience with combination BRAF/MEK inhibitors for melanoma with brain metastases: a real-life multicenter study.

Drago JZ, Lawrence D, Livingstone E, Zimmer L, Chen T, Giobbie-Hurder A, Amann VC, Mangana J, Siano M, Zippelius A, Dummer R, Goldinger SM, Sullivan RJ.

Melanoma Res. 2019 Feb;29(1):65-69. doi: 10.1097/CMR.0000000000000527.

PMID:
30376465
27.

Reply to emergency management of immune-related hypophysitis: Collaboration between specialists is essential to achieve optimal outcomes.

Faje AT, Sullivan RJ.

Cancer. 2018 Dec 15;124(24):4732. doi: 10.1002/cncr.31786. Epub 2018 Oct 23. No abstract available.

PMID:
30351493
28.

Publisher Correction: Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma.

Auslander N, Zhang G, Lee JS, Frederick DT, Miao B, Moll T, Tian T, Wei Z, Madan S, Sullivan RJ, Boland G, Flaherty K, Herlyn M, Ruppin E.

Nat Med. 2018 Dec;24(12):1942. doi: 10.1038/s41591-018-0247-8.

PMID:
30333558
29.

Mechanisms of Resistance to Immune Checkpoint Blockade.

Liu D, Jenkins RW, Sullivan RJ.

Am J Clin Dermatol. 2019 Feb;20(1):41-54. doi: 10.1007/s40257-018-0389-y. Review.

PMID:
30259383
30.

Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.

Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F, Zhao S, Das S, Beckermann KE, Ha L, Rathmell WK, Ancell KK, Balko JM, Bowman C, Davis EJ, Chism DD, Horn L, Long GV, Carlino MS, Lebrun-Vignes B, Eroglu Z, Hassel JC, Menzies AM, Sosman JA, Sullivan RJ, Moslehi JJ, Johnson DB.

JAMA Oncol. 2018 Dec 1;4(12):1721-1728. doi: 10.1001/jamaoncol.2018.3923. Erratum in: JAMA Oncol. 2018 Dec 1;4(12):1792.

31.

Results from phase II trial of HSP90 inhibitor, STA-9090 (ganetespib), in metastatic uveal melanoma.

Shah S, Luke JJ, Jacene HA, Chen T, Giobbie-Hurder A, Ibrahim N, Buchbinder EL, McDermott DF, Flaherty KT, Sullivan RJ, Lawrence DP, Ott PA, Hodi FS.

Melanoma Res. 2018 Dec;28(6):605-610. doi: 10.1097/CMR.0000000000000509.

PMID:
30211813
32.

Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma.

Auslander N, Zhang G, Lee JS, Frederick DT, Miao B, Moll T, Tian T, Wei Z, Madan S, Sullivan RJ, Boland G, Flaherty K, Herlyn M, Ruppin E.

Nat Med. 2018 Oct;24(10):1545-1549. doi: 10.1038/s41591-018-0157-9. Epub 2018 Aug 20. Erratum in: Nat Med. 2018 Dec;24(12):1942.

33.

Reply: Immunosuppression Does Not Reduce Antitumor Efficacy.

Mahmood SS, Sullivan RJ, Reynolds KL, Neilan TG.

J Am Coll Cardiol. 2018 Aug 7;72(6):702. doi: 10.1016/j.jacc.2018.06.005. No abstract available.

34.

The role of targeted therapy for melanoma in the immunotherapy era.

Sullivan RJ.

Semin Cutan Med Surg. 2018 Jun;37(2):112-119. doi: 10.12788/j.sder.2018.021.

PMID:
30040088
35.

Forestalling BRAF-Inhibitor Resistance in a Shocking Way.

Sullivan RJ.

Clin Cancer Res. 2018 Nov 15;24(22):5496-5498. doi: 10.1158/1078-0432.CCR-18-1344. Epub 2018 Jul 6.

PMID:
29980533
36.

High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma.

Faje AT, Lawrence D, Flaherty K, Freedman C, Fadden R, Rubin K, Cohen J, Sullivan RJ.

Cancer. 2018 Sep 15;124(18):3706-3714. doi: 10.1002/cncr.31629. Epub 2018 Jul 5.

37.

An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0.

Sullivan RJ, Atkins MB, Kirkwood JM, Agarwala SS, Clark JI, Ernstoff MS, Fecher L, Gajewski TF, Gastman B, Lawson DH, Lutzky J, McDermott DF, Margolin KA, Mehnert JM, Pavlick AC, Richards JM, Rubin KM, Sharfman W, Silverstein S, Slingluff CL Jr, Sondak VK, Tarhini AA, Thompson JA, Urba WJ, White RL, Whitman ED, Hodi FS, Kaufman HL.

J Immunother Cancer. 2018 May 30;6(1):44. doi: 10.1186/s40425-018-0362-6.

38.

Myocarditis Associated with Immune Checkpoint Inhibitors: An Expert Consensus on Data Gaps and a Call to Action.

Neilan TG, Rothenberg ML, Amiri-Kordestani L, Sullivan RJ, Steingart RM, Gregory W, Hariharan S, Hammad TA, Lindenfeld J, Murphy MJ, Moslehi JJ; Checkpoint Inhibitor Safety Working Group.

Oncologist. 2018 Aug;23(8):874-878. doi: 10.1634/theoncologist.2018-0157. Epub 2018 May 25.

39.

A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanoma.

Mooradian MJ, Reuben A, Prieto PA, Hazar-Rethinam M, Frederick DT, Nadres B, Piris A, Juneja V, Cooper ZA, Sharpe AH, Corcoran RB, Flaherty KT, Lawrence DP, Wargo JA, Sullivan RJ.

Oncoimmunology. 2018 Feb 1;7(5):e1423172. doi: 10.1080/2162402X.2017.1423172. eCollection 2018.

40.

Chiral auxiliary recycling in continuous flow: automated recovery and reuse of Oppolzer's sultam.

Sullivan RJ, Newman SG.

Chem Sci. 2018 Jan 25;9(8):2130-2134. doi: 10.1039/c7sc05192a. eCollection 2018 Feb 28.

41.

Dual MAPK/CDK Targeting in Melanoma: New Approaches, New Challenges.

Sullivan RJ.

Cancer Discov. 2018 May;8(5):532-533. doi: 10.1158/2159-8290.CD-18-0224.

42.

The Great Debate at "Melanoma Bridge", Napoli, December 2nd, 2017.

Ascierto PA, Caracò C, Gershenwald JE, Hamid O, Ross M, Sullivan RJ, Puzanov I.

J Transl Med. 2018 Apr 17;16(1):101. doi: 10.1186/s12967-018-1477-8.

43.

Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanoma.

Echevarría-Vargas IM, Reyes-Uribe PI, Guterres AN, Yin X, Kossenkov AV, Liu Q, Zhang G, Krepler C, Cheng C, Wei Z, Somasundaram R, Karakousis G, Xu W, Morrissette JJ, Lu Y, Mills GB, Sullivan RJ, Benchun M, Frederick DT, Boland G, Flaherty KT, Weeraratna AT, Herlyn M, Amaravadi R, Schuchter LM, Burd CE, Aplin AE, Xu X, Villanueva J.

EMBO Mol Med. 2018 May;10(5). pii: e8446. doi: 10.15252/emmm.201708446.

44.

Effect of ulixertinib, a novel ERK1/2 inhibitor, on the QT/QTc interval in patients with advanced solid tumor malignancies.

Mendzelevski B, Ferber G, Janku F, Li BT, Sullivan RJ, Welsch D, Chi W, Jackson J, Weng O, Sager PT.

Cancer Chemother Pharmacol. 2018 Jun;81(6):1129-1141. doi: 10.1007/s00280-018-3564-1. Epub 2018 Mar 30.

45.

Myocarditis in Patients Treated With Immune Checkpoint Inhibitors.

Mahmood SS, Fradley MG, Cohen JV, Nohria A, Reynolds KL, Heinzerling LM, Sullivan RJ, Damrongwatanasuk R, Chen CL, Gupta D, Kirchberger MC, Awadalla M, Hassan MZO, Moslehi JJ, Shah SP, Ganatra S, Thavendiranathan P, Lawrence DP, Groarke JD, Neilan TG.

J Am Coll Cardiol. 2018 Apr 24;71(16):1755-1764. doi: 10.1016/j.jacc.2018.02.037. Epub 2018 Mar 19.

46.

Corrigendum to "Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study*" [Eur J Cancer 91 (2018) 116-124].

Valpione S, Carlino MS, Mangana J, Mooradian MJ, McArthur G, Schadendorf D, Hauschild A, Menzies AM, Arance A, Ascierto PA, Giacomo AD, de Rosa F, Larkin J, Park JJ, Goldinger SM, Sullivan RJ, Xu W, Livingstone E, Weichenthal M, Rai R, Gaba L, Long GV, Lorigan P.

Eur J Cancer. 2018 Apr;93:158. doi: 10.1016/j.ejca.2018.02.001. Epub 2018 Mar 13. No abstract available.

PMID:
29548533
47.

Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors.

Moschos SJ, Sullivan RJ, Hwu WJ, Ramanathan RK, Adjei AA, Fong PC, Shapira-Frommer R, Tawbi HA, Rubino J, Rush TS 3rd, Zhang D, Miselis NR, Samatar AA, Chun P, Rubin EH, Schiller J, Long BJ, Dayananth P, Carr D, Kirschmeier P, Bishop WR, Deng Y, Cooper A, Shipps GW, Moreno BH, Robert L, Ribas A, Flaherty KT.

JCI Insight. 2018 Feb 22;3(4). pii: 92352. doi: 10.1172/jci.insight.92352. eCollection 2018 Feb 22.

48.

The impact of timing of immunotherapy with cranial irradiation in melanoma patients with brain metastases: intracranial progression, survival and toxicity.

Rahman R, Cortes A, Niemierko A, Oh KS, Flaherty KT, Lawrence DP, Sullivan RJ, Shih HA.

J Neurooncol. 2018 Jun;138(2):299-306. doi: 10.1007/s11060-018-2795-7. Epub 2018 Feb 16.

PMID:
29453679
49.

Molecular signatures of circulating melanoma cells for monitoring early response to immune checkpoint therapy.

Hong X, Sullivan RJ, Kalinich M, Kwan TT, Giobbie-Hurder A, Pan S, LiCausi JA, Milner JD, Nieman LT, Wittner BS, Ho U, Chen T, Kapur R, Lawrence DP, Flaherty KT, Sequist LV, Ramaswamy S, Miyamoto DT, Lawrence M, Toner M, Isselbacher KJ, Maheswaran S, Haber DA.

Proc Natl Acad Sci U S A. 2018 Mar 6;115(10):2467-2472. doi: 10.1073/pnas.1719264115. Epub 2018 Feb 16.

50.

Circulating BRAFV600E Levels Correlate with Treatment in Patients with Thyroid Carcinoma.

Lubitz CC, Zhan T, Gunda V, Amin S, Gigliotti BJ, Fingeret AL, Holm TM, Wachtel H, Sadow PM, Wirth LJ, Sullivan RJ, Panka DJ, Parangi S.

Thyroid. 2018 Mar;28(3):328-339. doi: 10.1089/thy.2017.0322. Epub 2018 Feb 27.

Supplemental Content

Loading ...
Support Center